文献速递眼整形与眼眶眼底病与葡萄膜炎

口服Hedgehog抑制剂维莫德吉治疗局部晚期眶周及眶内基底细胞癌:美国眼科学会报告

Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2024-07-10

该报告由美国眼科学会完成,检索PubMed至2023年9月的英文原始研究,纳入16篇文献,评估口服维莫德吉治疗局部晚期眶周及眶内基底细胞癌的疗效与安全性。多数研究显示高缓解率,但部分患者反应不完全、复发常见,且需手术或眶内容物剜除,不良反应普遍,分子分析显示所有患者切除组织均有残留肿瘤。

要点

  • 多数研究显示维莫德吉治疗眶周及眶内基底细胞癌缓解率高,个别研究达100%缓解,初治完全消退率最高达88%。
  • 12%的患者反应为部分缓解,复发频发,最高79.4%的患者需手术干预,最高23%仍需眶内容物剜除。
  • 不良反应常见,最高100%的患者经历至少1次事件,包括肌肉痉挛、脱发、体重下降、疲劳和味觉障碍,1例患者可能因治疗死于脓毒症。

核心结论

  • 尽管缺乏I级和II级证据,多数研究表明口服维莫德吉治疗眶周及眶内基底细胞癌可缩小肿瘤体积。
  • 应提醒患者注意治疗的不良反应以及肿瘤细胞持续存在并可能长期耐药的突变。
  • 维莫德吉作为短期新辅助治疗可能有效缩小肿瘤体积,以降低手术并发症,同时减少不良反应的频率和严重程度。

研究设计与样本

  • 美国眼科学会报告,通过PubMed数据库检索截至2023年9月的英文原始研究,评估口服维莫德吉对眶周及眶内基底细胞癌的效果。
  • 共识别60篇文章,16篇符合纳入标准。

主要发现

  • 多数研究显示高缓解率,个别研究中高达100%的患者对药物有反应,初始完全消退率高达88%。
  • 维莫德吉治疗导致肿瘤体积显著缩小,使大多数患者得以保留眼球。
  • 12%的患者反应为部分缓解,复发也以相当频率发生,即使在初始完全缓解后。
  • 高达79.4%的患者需要手术干预,高达23%的患者仍需眶内容物剜除。
  • 维莫德吉治疗后切除组织的分子分析显示所有患者均有残留肿瘤,并频繁出现可能赋予对进一步Hedgehog抑制剂治疗耐药的突变。

关键数值与推荐

  • 多数研究显示高缓解率,个别研究中高达100%的患者对药物有反应,初始完全消退率高达88%。
  • 12%的患者反应为部分缓解,复发也以相当频率发生。
  • 高达79.4%的患者需要手术干预,高达23%的患者仍需眶内容物剜除。
  • 分子分析显示所有患者切除组织均有残留肿瘤,并频繁出现可能耐药的突变。
  • 尽管大多数不良事件被评为I级或II级,但副作用常见,研究中高达100%的患者经历至少1次事件。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出维莫德吉作为短期新辅助治疗可能有效缩小肿瘤体积,以降低手术并发症,同时减少不良反应的频率和严重程度。
  • 作者指出应提醒患者注意治疗的不良反应以及肿瘤细胞持续存在并可能长期耐药的突变。

局限性

  • 原文指出缺乏I级和II级证据。
  • 分子分析显示维莫德吉治疗后所有患者切除组织均有残留肿瘤,并频繁出现可能赋予对进一步Hedgehog抑制剂治疗耐药的突变。
  • 1例患者可能因治疗死于脓毒症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the efficacy and safety of oral vismodegib (Erivedge; Genentech) in the management of locally advanced orbital and periorbital basal cell carcinoma (BCC). METHODS: A literature search was conducted last in September 2023 in the PubMed database for English language original research that evaluated the effect of oral vismodegib on orbital and periorbital BCC. Sixty articles were identified and 16 met the inclusion criteria. RESULTS: Most studies demonstrated high response rates, with up to 100% of patients responding to the medication in individual studies and initial complete regression occurring in up to 88% of patients. Vismodegib treatment resulted in significant reductions in tumor volume, resulting in globe preservation for most patients. However, in 12% of patients, the response was partial. Recurrences also occurred with substantial frequency, even after an initial complete response. As such, up to 79.4% of patients required surgical intervention, and up to 23% of patients still required exenteration. Use of these agents resulted in reductions in tumor volume that may delay or prevent the need for exenteration in some, but not all, patients. Importantly, molecular analysis of tissue excised after vismodegib therapy revealed persistent tumor in all patients, with frequent accumulation of mutations that may confer resistance to further hedgehog inhibitor therapy. Although most adverse events were rated as level I or II, side effects were common, with up to 100% of patients in studies experiencing at least 1 event. Muscle cramps, alopecia, weight loss, fatigue, and dysgeusia were the most common adverse events, and several patients discontinued therapy because of them. Furthermore, 1 patient died of sepsis that may have resulted from the therapy. CONCLUSIONS: Although level I and II evidence are lacking, most studies indicate a benefit from the use of oral vismodegib to treat orbital and periorbital BCC tumor volume. However, patients should be cautioned about the adverse side effects of treatment and the persistence of tumor cells with mutations that may cause long-term resistance. Use of vismodegib as short-term neoadjuvant therapy may be effective in shrinking tumor volume to reduce surgical morbidity while reducing the frequency and severity of side effects. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wladis EJ, Aakalu VK, Vagefi MR, et al. Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024. PMID: 39001766. doi:10.1016/j.ophtha.2024.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。